Paid Clinical Trials and Focus Groups by Location |
|
|
|
Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Condition: Heart Arrest
Intervention: Other: Preemptive Rapid Response Team intervention
Sponsors: University of Chicago; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Condition: Renal Impairment
Interventions: Drug: Febuxostat; Drug: Febuxostat; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified March 2010
Condition: Postoperative Pain
Intervention: Drug: cyclobenzaprine
Sponsor: NorthShore University HealthSystem Research Institute
Not yet recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitagliptin 2x50 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Heart Failure
Intervention: Biological: ACRX-100
Sponsor: Juventas Therapeutics, Inc.
Recruiting - verified March 2010
Condition: Individuals at Risk for Depression
Interventions: Behavioral: AIM Web based intervention + surveillance; Behavioral: AIM web based intervention; Behavioral: Educational website
Sponsor: Northwestern University
Recruiting - verified March 2010
Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: Indacaterol dose; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Condition: Epilepsy
Intervention: Drug: Diazepam
Sponsors: University of Chicago; King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Condition: Endotracheal Intubation
Interventions: Device: Airtraq; Other: Mac Blade Teaching First
Sponsor: Northwestern University
Recruiting - verified March 2010
Conditions: Discogenic Pain; Low Back Pain
Interventions: Procedure: Functional anesthetic discography; Procedure: Provocative Discography
Sponsors: Northwestern University; Medtronic Spine LLC
Recruiting - verified February 2010
Condition: Pregnancy
Intervention:
Sponsor: SPD Development Company Limited
Recruiting - verified February 2010
Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab; Drug: ranibizumab
Sponsors: Johns Hopkins University; Juvenile Diabetes Research Foundation
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Condition: Non-Hodgkin Lymphomas
Intervention: Drug: Ofatumumab
Sponsor: Oncology Specialists, S.C.
Recruiting - verified February 2010
Conditions: Pain; Surgery
Interventions: Drug: Placebo; Drug: (study group) will receive a bilateral TAP block using 15 cc of 0.5% ropivacaine on each side
Sponsor: Northwestern University
Recruiting - verified February 2010
Conditions: Pain; Obesity; Surgery
Interventions: Drug: Placebo; Drug: (study group) will receive a bilateral TAP block using 30 cc of 0.5% ropivacaine on each side.
Sponsor: Northwestern University
Recruiting - verified February 2010
Condition: Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention: Drug: KX2-391
Sponsor: Kinex Pharmaceuticals, LLC
Recruiting - verified March 2010
Condition: Atopic Dermatitis
Interventions: Other: Standard of care eczema treatment; Device: Accu-patch pellets
Sponsor: Northwestern University
Recruiting - verified February 2010
Conditions: Stage IV Colorectal Cancer; Dignity Therapy
Intervention: Behavioral: Dignity Therapy
Sponsor: Northwestern University
Not yet recruiting - verified February 2010
Condition: Diabetes Mellitus
Interventions: Device: Finesse; Device: Pen/Syringe (Usual injection device)
Sponsors: Calibra Medical, Inc.; Nancy Bohannon, MD, Med. Corp.; Henry Ford Health System; Northwestern University; University of Texas Southwestern Medical Center; Joslin Diabetes Center; International Diabetes Center at Park Nicollet
Recruiting - verified March 2010
Conditions: Pain; Breastfeeding
Intervention:
Sponsor: Northwestern University
Recruiting - verified February 2010
Condition: Postoperative Pain
Interventions: Drug: placebo; Drug: Study Drug (0.5% ropivacaine ) injection; Procedure: TAP block
Sponsor: Northwestern University
Not yet recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Placebo
Sponsor: Novartis
Recruiting - verified February 2010
Conditions: Sedentary Lifestyle; Risk of Disability; Aging
Intervention: Behavioral: Lifestyle modification
Sponsors: University of Florida; National Institute on Aging (NIA); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Procedure: Low-Level Laser Therapy
Sponsor: Northwestern University
Not yet recruiting - verified March 2010
Condition: Enteritis
Intervention: Drug: DOR201 (delayed release beclomethasone dipropionate)
Sponsors: Soligenix; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo; Drug: Tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Behavioral: Multimedia Education; Behavioral: Print Media; Behavioral: Usual and customary waiting room process
Sponsors: Saint Francis Care; American Cancer Society; Feinberg School of Medicine, Northwestern University
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: ASP1941; Drug: Metformin; Drug: Placebo
Sponsor: Astellas Pharma Inc
Not yet recruiting - verified February 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (info added by University of Michigan Data Coordinating Center)
Recruiting - verified November 2009
Condition: Insomnia
Intervention: Behavioral: cognitive behavioral therapy for insomnia (CBT-I)
Sponsor: University of Illinois
Recruiting - verified February 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Parkinson's Disease
Interventions: Drug: Amantadine; Drug: Placebo
Sponsors: Rush University Medical Center; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified February 2010
Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010
Condition: Abdominal Aortic Aneurysm
Interventions: Device: PEVAR (ProGlide closure); Device: SEVAR (IntuiTrak); Device: PEVAR (Prostar XL closure)
Sponsors: Endologix; Abbott Vascular
Not yet recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QAX028; Drug: QAX028; Drug: Tiotropium; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Conditions: Breast Cancer; Diagnostic Imaging
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Not yet recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01; Drug: Normal Saline
Sponsor: Alnylam Pharmaceuticals
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Mania; Bipolar I Disorder
Interventions: Drug: Cariprazine low dose; Drug: Cariprazine high dose; Drug: Placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified February 2010
Conditions: Bipolar Disorder; Mania
Interventions: Drug: Cariprazine; Drug: Placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
Condition: Congestive Heart Failure
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC
Recruiting - verified February 2010
Conditions: Vaginosis, Bacterial; Vaginal Infection
Interventions: Drug: GW05; Drug: GW05; Drug: GW05; Drug: Metronidazole
Sponsor: Graceway Pharmaceuticals, LLC
Recruiting - verified March 2010
Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone methyl (amorphous dispersion)
Sponsor: Reata Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsor: Mayo Clinic
Recruiting - verified March 2010
Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Placebo; Drug: Standard of Care
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Partial Epilepsy
Intervention: Drug: VX-765
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified March 2010
Conditions: Failed Back Surgery Syndrome; Leg Pain; Back Pain; Spinal Cord Stimulation
Interventions: Device: Precision Spinal Cord Stimulation; Procedure: Back Surgery
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
Condition: Alzheimer's Disease
Intervention: Drug: Semagacestat
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified February 2010
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Conditions: Barrett Syndrome; Barrett's Syndrome; Barrett's Esophagus; Barrett Esophagus; Adenocarcinoma
Interventions: Device: Standard endoscopic treatment of BE; Device: pCLE guided endoscopic treatment of BE
Sponsors: Mauna Kea Technologies; Cellvizio Inc.
Recruiting - verified February 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Metastatic Melanoma
Interventions: Drug: Cisplatin; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Intervention: Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
Sponsor: Novartis
Recruiting - verified March 2010
Condition: Insomnia
Interventions: Drug: MK4305; Drug: Comparator: Placebo to MK4305
Sponsor: Merck
Recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: BI 6727, IV infusion
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Leukemia
Intervention: Drug: AEG35156
Sponsor: Aegera Therapeutics
Recruiting - verified February 2010
Condition: Moderate to Severe Vasomotor Symptoms
Interventions: Drug: MK6913; Drug: Comparator: 17beta-estradiol; Drug: Comparator: placebo; Drug: Comparator: MK6913
Sponsor: Merck
Recruiting - verified March 2010
Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: Placebo; Drug: RO4917523; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Chronic Kidney Disease Stage 3 and 4
Interventions: Drug: Zemplar (paricalcitol) Capsules; Drug: Placebo capsules
Sponsor: Abbott
Recruiting - verified December 2009
Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: MEK inhibitor AZD6244; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer, Stage IIIb or IV
Intervention: Other: CHESS website for lung cancer patient + internet access if needed
Sponsors: University of Wisconsin, Madison; Harry Gray Cancer Center Hartford Hospial; M.D. Anderson Cancer Center; University of Illinois; University of Wisconsin Carbone Cancer Center
Recruiting - verified March 2010
Conditions: Back Pain; Chronic Low Back Pain; Internal Disc Disruption; Degenerative Disc Disease
Interventions: Biological: Biostat System; Drug: Sodium Chloride Injection
Sponsor: Spinal Restoration, Inc.
Recruiting - verified March 2010
Condition: Schizophrenia
Interventions: Drug: GSK239512; Drug: Placebo; Drug: d-amphetamine
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Active Rheumatoid Arthritis
Intervention: Drug: SBI-087
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tociliumab; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
Condition: Seasonal Allergic Rhinitis
Interventions: Drug: Veramyst /Artificial tears; Drug: Veramyst / Artificial tears lubricant eye drops; Drug: Veramyst nasal spray and Olopatadine eye drops; Other: Veramyst placebo and Olopatadine0.2% eye drops
Sponsors: University of Chicago; GlaxoSmithKline
Recruiting - verified November 2009
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875 6.25 mg; Drug: TAK-875 25 mg; Drug: TAK-875 50 mg; Drug: TAK-875 100 mg; Drug: TAK-875 200 mg; Drug: Glimepiride 2 mg or 4mg; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Rotator Cuff Deficiency; Shoulder Arthropathy; Failed Shoulder Replacement
Intervention: Device: Encore Reverse Shoulder Prosthesis (RSP®)
Sponsor: Encore Medical, L.P.
Recruiting - verified March 2010
Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: DNA ploidy analysis; Genetic: fluorescence in situ hybridization; Genetic: microsatellite instability analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Abdominal Pain Upper
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified February 2010
Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease
Interventions: Drug: Darapladib 160 mg; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified February 2010
Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Posttraumatic Stress Disorder (PTSD)
Interventions: Drug: orvepitant; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Arrhythmia Prophylaxis
Interventions: Drug: Celivarone (SSR149744); Drug: amiodarone; Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: belinostat; Drug: carboplatin
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Rhinosinusitis
Intervention: Device: FinESS Sinus Treatment
Sponsor: Entellus Medical, Inc.
Recruiting - verified March 2010
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Tamibarotene; Drug: Arsenic trioxide
Sponsor: Northwestern University
Recruiting - verified February 2010
Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Cyclosporins; Drug: nab-paclitaxel
Sponsors: Northwestern University; Avon Foundation
Recruiting - verified February 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2009
Condition: Pain
Intervention: Drug: oxycodone immediate release (OXYRX)
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Coronary Artery Disease
Interventions: Drug: Placebo & Aspirin; Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors: Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Bristol-Myers Squibb; Sanofi-Synthelabo; Cordis Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.; Medtronic
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Other: Side-effect questionnaires; Other: research blood samples
Sponsors: University of Chicago; Translational Breast Cancer Reserach Consortium; National Institutes of Health (NIH)
Recruiting - verified February 2010
Condition: Schizophrenia
Interventions: Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: GW856653; Other: Placebo; Drug: GW856653
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation
Interventions: Drug: Placebo; Drug: Cinacalcet
Sponsor: Amgen
Not yet recruiting - verified March 2010
Condition: Parkinson's Disease
Interventions: Drug: IPX066; Drug: regular carbidopa-levodopa
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified March 2010
Condition: Psoriasis
Interventions: Drug: AMG 827; Drug: AMG 827; Drug: AMG 827; Drug: AMG 827; Drug: Placebo
Sponsor: Amgen
Not yet recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: placebo; Biological: golimumab; Biological: golimumab; Biological: golimumab
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Gastroesophageal Reflux
Interventions: Drug: Rabeprazole sodium capsules; Drug: placebo; Drug: Rabeprazole sodium capsules
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: JNJ-28431754
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Asthma
Interventions: Biological: MEDI-528; Biological: MEDI-528; Biological: MEDI-528; Other: Placebo
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Degenerative Disc Disease
Intervention:
Sponsor: Orthofix, Inc.
Recruiting - verified February 2010
Condition: Paroxysmal Atrial Fibrillation
Interventions: Procedure: Atrial Fibrillation ablation procedure; Device: NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL
Sponsor: Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Vertebral Compression Fractures
Intervention: Device: OsseoFix Spinal Fracture Reduction System
Sponsor: Alphatec Spine, Inc.
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Not yet recruiting - verified February 2010
Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Metformin XR; Drug: Metformin XR
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Alcoholism
Interventions: Drug: Ethanol; Drug: Placebo; Drug: Diphenhydramine; Drug: Caffeine
Sponsors: University of Chicago; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified March 2010
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Conditions: Breast Cancer; Hot Flashes; Menopausal Symptoms; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: flaxseed; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Condition: Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Subjective Tinnitus
Interventions: Drug: Neramexane mesylate; Drug: Placebo
Sponsor: Merz Pharmaceuticals GmbH
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
Sponsor: Shire Human Genetic Therapies, Inc.
Available - verified March 2010
Condition: Anemia
Intervention: Drug: Epoetin alfa
Sponsors: Stanford University; National Institute on Aging (NIA)
Recruiting - verified February 2010
Condition: Myelofibrosis
Interventions: Drug: INCB018424; Drug: Placebo
Sponsor: Incyte Corporation
Recruiting - verified March 2010
Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Sickle Cell Disease; Secretory Phospholipase A2; sPLA2
Interventions: Biological: Single blood transfusion; Behavioral: Standard care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: AMG 827 70 mg; Drug: AMG 827 140 mg; Drug: AMG 827 210 mg; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Condition: Asthma
Intervention: Drug: JNJ39758979
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Cervical Disc Disease
Intervention: Device: Zero-P PEEK
Sponsor: Synthes Spine
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Degenerative Disc Disease With or Without Stenosis
Intervention: Device: chronOS strip
Sponsor: Synthes Spine
Recruiting - verified March 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cytomegalovirus Infection
Interventions: Drug: CMX001; Drug: Placebo
Sponsor: Chimerix
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: MET tyrosine kinase inhibitor PF-02341066; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Polycythemia Vera
Interventions: Drug: Clopidogrel (Plavix); Drug: Placebo; Drug: Aspirin
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Clazosentan; Drug: Clazosentan; Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327 10 mg; Other: Prednisone Placebo; Drug: PF-04171327 25 mg; Other: Prednisone Placebo; Drug: Prednisone 5 mg; Other: Placebo for PF-04171327; Other: Placebo; Other: Placebo for PF-04171327
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Neoplasms; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma of Unknown Primary
Interventions: Drug: carboplatin; Drug: everolimus; Drug: paclitaxel; Genetic: gene expression analysis; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: obatoclax mesylate; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Amyloid Cardiomyopathy
Intervention: Drug: Fx-1006A
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Condition: Schizophrenia
Interventions: Drug: oral risperidone; Drug: paliperidone palmitate
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Bronchopulmonary Dysplasia
Interventions: Drug: Inhaled Nitric Oxide; Drug: Placebo
Sponsor: INO Therapeutics
Recruiting - verified March 2010
Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocytopenia
Interventions: Drug: Panobinostat; Drug: Panobinostat
Sponsor: Novartis
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Metastatic Colorectal Cancer
Intervention: Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Degenerative Disc Disease
Intervention: Device: NUBAC™
Sponsor: Pioneer Surgical Technology, Inc.
Recruiting - verified February 2010
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Contrast Induced Nephropathy
Intervention: Drug: sodium bicarbonate
Sponsor: MD Scientific
Recruiting - verified February 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
Condition: Phenylketonuria
Intervention: Drug: rAvPAL-PEG
Sponsor: BioMarin Pharmaceutical
Recruiting - verified March 2010
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Gastric Cancer; Adenocarcinoma
Interventions: Biological: IMC-1121B; Other: Placebo; Other: Best Supportive Care
Sponsor: ImClone LLC
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3; Drug: liposomal doxorubicin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified November 2009
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12; Drug: sorafenib
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Cystic Fibrosis
Interventions: Drug: SB656933; Drug: Placebo; Drug: SB656933
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Conditions: Herpes Zoster; Shingles
Interventions: Drug: valacyclovir; Drug: FV-100; Drug: FV-100; Drug: Valacyclovir placebo; Drug: FV-100 placebo
Sponsor: Inhibitex
Recruiting - verified February 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Genetic: microarray analysis; Other: laboratory biomarker analysis
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Alzheimer Disease
Intervention: Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
Condition: End Stage Renal Disease
Intervention: Procedure: Graft placement surgery plus Trinam therapy
Sponsor: Ark Therapeutics Ltd
Recruiting - verified December 2009
Condition: Glioblastoma Multiforme
Intervention: Drug: Azixa
Sponsor: Myriad Pharmaceuticals
Recruiting - verified February 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: capecitabine; Drug: sunitinib malate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Crohn's Disease
Interventions: Drug: certolizumab pegol; Drug: certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified February 2010
Condition: Solid Organ Malignancy
Interventions: Drug: Amrubicin; Drug: Cyclophosphamide
Sponsors: Hoosier Oncology Group; Celgene Corporation
Recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release Dose A; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Chronic Heart Failure
Interventions: Drug: LCZ696; Drug: Valsartan
Sponsor: Novartis
Recruiting - verified February 2010
Condition: Coronary Artery Chronic Total Occlusion
Intervention: Device: Recanalization of a coronary chronic total occlusion
Sponsor: BridgePoint Medical
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fibromyalgia; Sleep Disorders
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gabapentin; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Depression
Interventions: Other: Placebo; Drug: orvepitant
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified February 2010
Condition: Herpes Labialis
Intervention: Drug: Famciclovir
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Euvolemic Hyponatremia
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified February 2010
Conditions: Down Syndrome; Trisomy 21
Intervention:
Sponsors: Women and Infants Hospital of Rhode Island; Sequenom, Inc.
Recruiting - verified February 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: tetomilast; Drug: placebo
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Cetuximab; Drug: Gemcitabine; Drug: Carboplatin; Biological: IMC-A12; Drug: Cisplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Chronic Rhinosinusitis
Interventions: Procedure: Pre-treatment Sinus CT Scan; Procedure: Post-treatment Sinus CT Scan
Sponsor: Northwestern University
Recruiting - verified February 2010
Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Bipolar Depression
Interventions: Drug: lurasidone + (lithium or divalproex); Drug: Placebo + (lithium or divalproex)
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Conditions: Bipolar; Depression
Interventions: Drug: lurasidone; Drug: lurasidone; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Bipolar I, Depression
Intervention: Drug: lurasidone
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: graft-versus-tumor induction therapy; Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: quality-of-life assessment
Sponsors: Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: HIV Infections; Peripheral Neuropathy
Interventions: Drug: Duloxetine; Drug: Duloxetine placebo; Drug: Methadone; Drug: Methadone placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Dasatinib; Drug: Leuprolide Acetate (LHRH Analogue); Procedure: Radical Prostatectomy
Sponsors: Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified February 2010
Conditions: Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Malignant Glioma
Interventions: Drug: LBH589; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genentech; Novartis
Recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Interventions: Drug: eszopiclone; Drug: eszopiclone; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Condition: Optic Neuritis
Interventions: Drug: Glatiramer Acetate (Copaxone); Drug: placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Intervention: Drug: eszopiclone
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: MetMAb; Drug: placebo
Sponsor: Genentech
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP 690,550; Drug: CP-690,550; Other: Placebo; Other: Placebo; Biological: Biologic TNFi
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Mild Traumatic Brain Injury
Intervention:
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified February 2010
Condition: Ventricular Tachycardia
Intervention: Device: Magnetic irrigated catheter for VT
Sponsor: Stereotaxis
Recruiting - verified February 2010
Condition: Colorectal Cancer (CRC)
Interventions: Drug: Irinotecan; Drug: 5-Fluorouracil (bolus); Drug: 5-Fluorouracil (infusional); Drug: Leucovorin calcium; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab Placebo (saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: B-Cell Lymphoma; B-Cell Leukemia
Intervention: Drug: PCI-32765
Sponsor: Pharmacyclics
Recruiting - verified July 2009
Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: Cetuximab; Drug: Irinotecan; Biological: IMC-A12
Sponsors: ImClone LLC; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified February 2010
Conditions: Chronic Sinusitis; Chronic Rhinosinusitis; Nasal Polyps
Intervention: Drug: Prednisone
Sponsor: Northwestern University
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: idarubicin; Drug: pravastatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Procedure: Blood drawn for laboratory testing
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Acute Decompensated Heart Failure
Intervention: Drug: CD-NP
Sponsor: Nile Therapeutics
Recruiting - verified March 2010
Condition: Phenylketonuria
Intervention: Drug: sapropterin dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified March 2010
Condition: Opioid Dependency
Intervention: Drug: VIVITROL
Sponsor: Alkermes
Recruiting - verified February 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Parkinson Disease
Interventions: Drug: Placebo; Drug: inosine; Drug: inosine
Sponsors: The Parkinson Study Group; Massachusetts General Hospital; Harvard School of Public Health; University of Rochester; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified March 2010
Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus-1
Interventions: Drug: maraviroc; Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Epidermolysis Bullosa
Intervention: Drug: Alwextin cream
Sponsors: Northwestern University; Children's Memorial Hospital
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Hedgehog antagonist GDC-0449; Genetic: gene expression analysis; Genetic: in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Psoriasis Vulgaris
Intervention: Drug: Calcipotriene plus betamethasone dipropionate ointment
Sponsor: LEO Pharma
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Device: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Sponsor: U-Systems, Inc.
Recruiting - verified February 2010
Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Conditions: Hepatitis C; Hepatitis C Virus
Interventions: Drug: Fluvastatin; Drug: Peginterferon alfa2a; Drug: ribavirin
Sponsor: University of Chicago
Recruiting - verified February 2010
Condition: Metastatic Colorectal Cancer
Interventions: Biological: AMG 479; Other: Placebo; Other: FOLFIRI; Biological: AMG 655
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Condition: Neoplasms
Interventions: Drug: RG1507; Drug: gemcitabine; Drug: erlotinib [Tarceva]; Drug: paclitaxel; Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: etoposide; Drug: mFOLFOX6; Drug: capecitabine [Xeloda]; Drug: trastuzumab [Herceptin]; Drug: sorafenib; Drug: irinotecan; Drug: cetuximab; Drug: temozolomide; Drug: docetaxel; Drug: pemetrexel; Drug: RO1507
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified February 2010
Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: infliximab; Drug: methotrexate; Drug: methylprednisolone; Drug: ocrelizumab; Drug: sham
Sponsor: Genentech
Recruiting - verified February 2010
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: CS7017 tablets; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: sirolimus; Drug: tacrolimus; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Psoriasis
Interventions: Drug: etanercept / placebo; Drug: placebo / etanercept
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified February 2010
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cladribine; Drug: temsirolimus; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pulmonary Fibrosis
Intervention: Drug: CNTO 888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: pregabalin; Drug: LY545694; Drug: LY545694; Drug: LY545694
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg; Drug: Comparator: rosuvastatin 10 mg; Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg; Drug: Comparator: rosuvastatin 20 mg
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Hematologic Disease; Blood Coagulation Disorders
Interventions: Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Phenylketonuria; Hyperphenylalaninaemia
Intervention: Drug: Sapropterin Dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified January 2010
Condition: Lung Cancer
Interventions: Other: clinical observation; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: vorinostat (an HDAC inhibitor); Drug: bortezomib
Sponsor: Merck
Recruiting - verified February 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Condition: Back Pain
Interventions: Drug: placebo; Drug: tapentadol IR; Drug: oxycodone IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Not yet recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Intensive Care Unit
Intervention: Drug: ceftobiprole
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: axitinib; Drug: axitinib; Drug: chemotherapy; Drug: axitinib; Drug: chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hemophilia B
Interventions: Biological: IB1001 (On-Demand); Biological: IB1001 (Prophylaxis)
Sponsor: Inspiration Biopharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Glioblastoma Multiforme
Interventions: Drug: CT-322; Drug: Temozolomide; Procedure: Radiation Therapy
Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
Recruiting - verified March 2010
Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: Vicriviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2009
Condition: Scleroderma
Intervention: Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Acromegaly
Interventions: Drug: Octreotide Implant; Drug: Sandostatin LAR Depot
Sponsor: Endo Pharmaceuticals Solutions Inc.
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Gastroparesis; GERD; Esophagitis
Intervention: Drug: Domperidone
Sponsor: Greenberg, Eugene, M.D.
Recruiting - verified February 2010
Conditions: Graft vs Host Disease; Graft-Versus-Host Disease
Intervention: Drug: Prochymal®
Sponsors: Osiris Therapeutics; Quintiles
Available - verified February 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: taspoglutide; Drug: placebo; Drug: pioglitazone; Drug: metformin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
Sponsor: Morphotek
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lymphoma; Neurotoxicity
Interventions: Biological: rituximab; Drug: cytarabine; Drug: methotrexate; Drug: motexafin gadolinium; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Robert H. Lurie Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Major Depressive Disorder (MDD)
Intervention: Drug: repeat dose
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2189265; Drug: Sitagliptin 100mg, 24 months; Drug: Placebo solution; Drug: Placebo tablet, 6 months; Drug: Placebo tablet, 24 months; Drug: Sitagliptin 100 mg, 18 months
Sponsors: Eli Lilly and Company; United BioSource Corporation; Tessella Inc.; Berry Consultants
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Radiation: Radiation Therapy
Sponsors: Hoosier Oncology Group; Eli Lilly and Company
Recruiting - verified February 2010
Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Clindamycin; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Conditions: Hereditary Clear Cell Renal Cell Carcinoma; Kidney Cancer
Interventions: Drug: sorafenib tosylate; Genetic: TdT-mediated dUTP nick end labeling assay; Other: immunohistochemistry staining method; Procedure: diffusion-weighted magnetic resonance imaging
Sponsors: Robert H. Lurie Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Colorectal Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic laparoscopic surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Fibromyalgia
Intervention: Drug: Treatment for Fibromyalgia
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Lymphoma; Hodgkin Disease; Lymphoma, Non-Hodgkin
Intervention: Drug: PCI-24781
Sponsor: Pharmacyclics
Recruiting - verified December 2009
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: iloprost
Sponsor: Actelion
Recruiting - verified February 2010
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 0.1 mg/kg; Biological: PF-04360365 0.5 mg/kg; Biological: PF-04360365 1 mg/kg; Drug: Placebo; Biological: PF-04360365 3 mg/kg; Biological: PF-04360365 8.5 mg/kg
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: pegylated liposomal doxorubicin (PLD); Drug: EC20; Drug: EC20
Sponsor: Endocyte
Recruiting - verified February 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: Standard anti-rheumatic treatment
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: vandetanib; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Relapsed Follicular Lymphoma
Interventions: Drug: VELCADE, rituximab, cyclophosphamide, prednisone, and Doxorubicin; Drug: VELCADE, rituximab, cyclophosphamide, and prednisone
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Ischemic Stroke
Intervention: Behavioral: Imitate Therapy
Sponsors: University of Chicago; National Institute on Deafness and Other Communication Disorders (NIDCD); Rehabilitation Institute of Chicago
Recruiting - verified March 2010
Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: placebo
Sponsors: Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010
Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor: Cubist Pharmaceuticals
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsor: Agennix
Recruiting - verified March 2010
Condition: Transitional Cell Carcinoma of the Bladder
Interventions: Drug: Dasatinib; Procedure: Radical Cystectomy
Sponsors: Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Metastatic Melanoma
Intervention: Other: Photoimmunotherapy
Sponsor: Northwestern University
Recruiting - verified February 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; Genzyme; National Institutes of Health (NIH)
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Biological: IMCL-1121B
Sponsor: ImClone LLC
Recruiting - verified March 2010
Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Diabetic Retinopathy; Diabetes Complications
Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: nsNSAIDs
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Metabolic Complications
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: Rush University Medical Center; Eli Lilly and Company
Recruiting - verified February 2010
Condition: Thromboembolism
Interventions: Drug: Dabigatran etexilate; Drug: Warfarin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Dyslipidemias; Coronary Heart Disease; Kidney Disease
Interventions: Drug: ABT-335; Drug: Rosuvastatin; Drug: Placebo
Sponsors: Abbott; AstraZeneca
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Conditions: Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention: Drug: CEP-701 (Lestaurtinib)
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Conditions: Polycythemia Vera; Essential Thrombocythemia; Idiopathic Myelofibrosis
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Conditions: Myeloproliferative Disease; Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Adenocarcinoma of the Ovary
Intervention: Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Sponsor: AVAX Technologies
Recruiting - verified March 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
Sponsors: M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Atrial Septal Defect
Intervention: Device: AMPLATZER Septal Occluder
Sponsor: AGA Medical Corporation
Recruiting - verified January 2009
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Pulmonary Fibrosis
Interventions: Drug: Prednisone; Drug: Azathioprine; Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Ventricular Septal Defects
Intervention: Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
Sponsor: AGA Medical Corporation
Recruiting - verified October 2009
Condition: Chronic Angina
Intervention: Drug: Ranolazine
Sponsor: Gilead Sciences
Recruiting - verified February 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2009
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Ocular Safety
Intervention: Drug: Observational Study
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Squamous Cell
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: TTR-associated Amyloidosis
Intervention: Other: THAOS is a noninterventional patient registry
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: aflibercept
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Immunosuppression; Kidney Transplantation; Graft Rejection
Intervention: Procedure: Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Sponsors: Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
Conditions: Dyslipidemias; Carotid Artery Disease; Coronary Heart Disease
Interventions: Drug: ABT-335; Drug: Placebo
Sponsor: Abbott
Recruiting - verified January 2010
Condition: Hemophilia A
Interventions: Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS); Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Placebo; Drug: Cisplatin; Drug: Etoposide; Drug: ZD6474
Sponsors: Hoosier Oncology Group; AstraZeneca
Recruiting - verified February 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Head and Neck Cancer
Interventions: Biological: IMC-A12; Biological: cetuximab
Sponsor: ImClone LLC
Recruiting - verified March 2010
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Conditions: Attention Deficit Hyperactivity Disorder; Dyslexia
Interventions: Drug: Atomoxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Infrarenal Abdominal Aortic Aneurysm
Intervention: Device: Anaconda Stent Graft System
Sponsors: Terumo CVS; Vascutek Ltd., Scotland
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: capecitabine; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Conditions: Osteosarcoma; Sarcoma, Ewing's; Peripheral Neuroectodermal Tumor
Interventions: Drug: SCH 717454 (19D12); Drug: SCH 717454 (19D12)
Sponsor: Schering-Plough
Recruiting - verified February 2010
Condition: Prostatic Hyperplasia
Interventions: Drug: Polyphenon E, 200 mg EGCG bid; Drug: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Liquid Certolizumab pegol; Drug: Liquid Certolizumab pegol; Other: Placebo; Drug: Methotrexate
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Conditions: Pneumonia; Pneumonia, Bacterial
Interventions: Drug: doripenem; Drug: imipenem/cilastatin
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Drug: cediranib maleate; Drug: irinotecan hydrochloride
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Hyponatremia
Interventions: Drug: lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified February 2010
Conditions: Esophageal Cancer; Adenocarcinoma of the Esophagus; Squamous Cell Carcinoma
Interventions: Drug: OncoGel (Paclitaxel gel); Drug: cisplatin; Drug: 5-FU; Radiation: radiation therapy; Procedure: esophageal resection
Sponsor: Protherics
Recruiting - verified March 2010
Condition: Myelofibrosis
Intervention: Drug: Fludarabine, Melphalan +/- ATG
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Grou
All Locations ... United States » ... Illinois 
